Metachromatic leukodystrophy is a rare genetic disorder that mainly affects young children and results in severe neurological symptoms accompanied by a loss of motor and intellectual capacities. At Paris Brain Institute, Françoise Piguet and her colleagues have developed a gene therapy treatment capable of correcting the primary anomaly observed in the disease: the accumulation of sulfatides in the brain and spinal cord. Effective in mice, as shown by new results published in Molecular Therapy – Methods & Clinical Development, this technique paves the way for human clinical trials.
Metachromatic leukodystrophy is a rare genetic disorder that affects between 1 and 9 people out of 100,000 and manifests itself mainly in childhood and adolescence—with 10 to 20% of cases observed in adulthood. The disease is hereditary but requires both parents to carry the mutated ARSA gene, which controls the production of the enzyme arylsulfatase A. The depletion of this enzyme in the body leads to an abnormal accumulation of specific lipids (sulfatides) in the white matter of the central nervous system, peripheral nerves, kidneys and gallbladder.
The consequence? A loss of the myelin sheath, which ensures proper conduction of nerve signals in the brain and spinal cord, and an acute inflammatory response that damages nerve cells. As a result, patients experience severely debilitating symptoms such as movement, vision and hearing disorders, a deterioration in intellectual abilities and difficulty expressing themselves. Metachromatic leukodystrophy progresses particularly rapidly in children and leads to premature death, hence the urgent need to develop effective treatments.
For these young patients whose symptoms have already set in, gene therapy—which involves injecting a healthy gene into the body using a harmless virus—is a very promising way of delaying or halting the progression of the disease. This technique makes it possible to make nerve cells express the protein lacking—in this case, the enzyme arylsulfatase A.” However, a crucial constraint must be overcome for in vivo gene therapy to be effective: allowing the cargo of genetic material to cross the blood-brain barrier, which prevents unwanted substances circulating in the blood from reaching the brain.
Tackling the blood-brain barrier
For their study, Françoise Piguet and her team chose a specific type of “adeno-associated” virus (AAVPHP.eB) whose properties enable it to cross this barrier easily and is harmless for the body. The researchers used it as a vector—or as a vehicle—to carry a copy of the functional ARSA gene into the brains of mice in which this gene was deficient.
“We administered the drug-gene to six-month-old mice and then to nine-month-old mice with more severe symptoms,” Françoise Piguet adds. “The effects of the treatment were then assessed three and six months after each injection.”
The researchers' results are very encouraging. The healthy gene successfully spread to the target neuron population, which began secreting the precious enzyme and correcting the activity of nearby cells—including myelin-producing oligodendrocytes. The result? Sulfatide levels returned to normal, and neuroinflammation was significantly reduced in the brain and spinal cord, even in the nine-month-old mice with more advanced disease.
These data are robust enough that we can now evaluate the treatment in primates to organize clinical trials in humans later. Metachromatic leukodystrophy sets in rapidly in young children, and gene therapy must stop the abnormal accumulation of sulfatides almost immediately. All our efforts are devoted to achieving this goal!
Funding
This project was funded by the European Leukodystrophy Association, JANSSEN Horizon, and the NeurATRIS “Investissements d'avenir” program.
Sources
Audouard, E. et al. Dose-response evaluation of intravenous gene therapy in a symptomatic mouse model of metachromatic leucodystrophy. Molecular Therapy – Methods & Clinical Development, Avril 2024. DOI : 10.1016/j.omtm.2024.101248.
